Background Various studies have assessed omalizumab outcomes in the clinical practice
setting but follow‐up and/or number of patients included were limited. We aim to describe …

Asthma and food allergy are two complex allergic diseases with an increasing prevalence in
childhood. They share risk factors, including atopic family history, atopic dermatitis, allergen …

Background The allergic phenotype is responsible for more than 50% of severe asthma
cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe …

Objectives Although several randomized clinical trials performed in children 6 years and
older with Omalizumab as add‐on therapy have reported improvements in diverse clinical …

Introduction Dupilumab is an effective and safe medicine for the management of severe
asthma. Due to its high cost, concerns are generated regarding its cost‐effectiveness. This …

Background Omalizumab has been approved for treating moderate-to-severe asthma in
children aged over 6 years. Its application to asthmatic children with other allergic diseases …

Introduction An important proportion of asthma patients remain uncontrolled despite using
inhaled corticosteroids and long-acting beta-agonists. Some add-on therapies, such as …

Antecedentes La prevalencia de asma grave en Latinoamérica oscila entre 5 y 20%. 1 El
estudio Asthma Insights and Realista in Latin America Survey de 2005 reportó una …

Background An important proportion of asthma patients remain uncontrolled despite the use
of inhaled corticosteroids and long-acting beta-agonists. Some add-on therapies, like …

Antecedentes: El “asma bronquial” es un trastorno de tipo inflamatorio de la vía aérea, se
menciona que es una de las patologías crónicas más frecuentes, tanto en adultos como en …